Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19.
Johannes C FischerAlbrecht G SchmidtEdwin BoelkeMarkus UhrbergVerena KeitelTorsten FeldtBjörn JensenDieter HäussingerOrtwin AdamsE Marion SchneiderVera BalzJürgen EnczmannJutta RoxDerik HermsenKarin Schulze-BosseDetlef Kindgen-MillesWolfram Trudo KnoefelMartijn van GriensvenJan HaussmannBalint TamaskovicsChristian PlettenbergKathrin ScheckenbachStefanie CorradiniAlessia PedotoKitti MaasLivia SchmidtOlaf GrebeIrene EspositoAnja EhrhardtMatthias PeiperBettina Alexandra BuhrenChristian CallesAndreas StöhrArtur LichtenbergNoemi F FreiseMatthias LutterbeckAmir RezazadehWilfried BudachChristiane MatuschekPublished in: European journal of medical research (2021)
The current study shows that the presence of HLA class II DRB1*01:01 and HLA class I B*35:01 is of even stronger association with reduced disease duration in mild and moderate COVID-19 than age or any other potential risk factor assessed. Prospective studies in larger patient populations also including novel SARS-CoV-2 variants will be required to assess the impact of HLA genetics on the capacity of mounting protective vaccination responses in the future.